Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

MLA

E. Fontana, et al. “Efficacy Signals, Long-Term Exposure and Safety Data from a Phase 1–2 Study of a Cell-Penetrating Peptide Antagonist of CEBPβ, a Novel Target, in Patients (Pts) with Refractory Solid Tumors.” European Journal of Cancer, vol. 174, Oct. 2022, pp. S82–83. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........15d6575b9e13e8c8f841cc16ff92e868&authtype=sso&custid=ns315887.

APA

E. Fontana, A. Williams, G. Falchook, N. Lakhani, T.R.J. Evans, V. Gondi, F. Iwamoto, M. McKean, S. Symeonides, N. Butowski, A. McLaren, J. Henry, R. Buerki, J. Rotolo, G. Capiaux, R. Michel, S. Kaesshaefer, E. Wiegert, & A. Bexon. (2022). Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. European Journal of Cancer, 174, S82–S83.

Chicago

E. Fontana, A. Williams, G. Falchook, N. Lakhani, T.R.J. Evans, V. Gondi, F. Iwamoto, et al. 2022. “Efficacy Signals, Long-Term Exposure and Safety Data from a Phase 1–2 Study of a Cell-Penetrating Peptide Antagonist of CEBPβ, a Novel Target, in Patients (Pts) with Refractory Solid Tumors.” European Journal of Cancer 174 (October): S82–83. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........15d6575b9e13e8c8f841cc16ff92e868&authtype=sso&custid=ns315887.